Home LiteratureArticle Details
PMID: 8932918 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Maternal exposure to potential inhibitors of DNA topoisomerase II and infant leukemia (United States): a report from the Children's Cancer Group.

Cancer causes & control : CCC ·Vol. 7 ·No. 6 ·1996-11-00 ·Pages 581-90

Ross JA, Potter JD, Reaman GH, Pendergrass TW, Robison LL

Abstract

Nearly 80 percent of infant leukemias present with an abnormality involving the MLL gene at 11q23. Moreover, secondary acute myeloid leukemias (AML) that occur as the result of chemotherapy agents, which are known to inhibit DNA topoisomerase II, often manifest the same MLL abnormalities. It has been hypothesized that de novo infant leukemias may occur as a result of maternal exposure to agents in diet and medications that inhibit DNA topoisomerase II. Three epidemiologic studies of childhood leukemia with similar methodologies were conducted in the United States and Canada over the past 10 years by the Children's Cancer Group (CCG). Of the total 771 mothers of infants diagnosed at one year of age or less (< 12.5 months) who originally were interviewed (303 infant cases and 468 matched controls) across the three studies, follow-up questionnaire data on maternal exposure to potential DNA topoisomerase II inhibitors during pregnancy were available on 84 cases and 97 matched controls in the US. For maternal diet, a composite variable was created that consisted of 10 foods identified alpha priori as containing DNA topoisomerase II inhibitors. There were no significant trends with increasing maternal consumption for either the overall group, or the acute lymphoblastic leukemia (ALL) stratum. However, within the AML stratum, there was a statistically significant positive association (P trend = 0.04) with increasing consumption of DNA topoisomerase II-inhibitor containing foods (odds ratio [OR] = 9.8, 95 percent confidence interval [CI] = 1.1-84.8; OR = 10.2, CI = 1.1-96.4; for medium and high consumption, respectively). Other potential topoisomerase II inhibitors were explored; no significant findings were found. Results of this preliminary study, in combination with molecular data, should be used in future investigations of childhood leukemia (particularly, infant) to justify the incorporation of a detailed dietary history.

MeSH Terms
Acute Disease Canada/epidemiology Case-Control Studies Chromosomes, Human, Pair 11/genetics Confidence Intervals Diet/adverse effects Drug-Related Side Effects and Adverse Reactions Female Follow-Up Studies Food Genes/genetics Humans Infant Interviews as Topic Leukemia/epidemiology Leukemia, Myeloid/epidemiology Maternal Exposure/adverse effects,statistics & numerical data Odds Ratio Precursor Cell Lymphoblastic Leukemia-Lymphoma/epidemiology Pregnancy Surveys and Questionnaires Topoisomerase II Inhibitors United States/epidemiology
Chemicals
Topoisomerase II Inhibitors
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Ross J A
Division of Pediatric Epidemiology and Clinical Research, University of Minnesota, Minneapolis, USA.
Potter J D
Reaman G H
Pendergrass T W
Robison L L
References (24)
24 references, click to expand
  1. Induction of mammalian topoisomerase II dependent DNA cleavage by nonintercalative flavonoids, genistein and orobol.
    Biochem Pharmacol. 1990 Feb 15;39(4):737-44 PMID: 2154993
  2. Chromosomal changes in Chinese hamster AA8 cells caused by podophyllin, a common treatment for genital warts.
    Mutat Res. 1992 Apr;266(2):231-9 PMID: 1373833
  3. Assessment of environmental and genetic factors in the etiology of childhood cancers: the Childrens Cancer Group epidemiology program.
    Environ Health Perspect. 1995 Sep;103 Suppl 6:111-6 PMID: 8549456
  4. Therapy of genital human papillomavirus infections. Part II: Methods of treatment.
    Int J Dermatol. 1992 Nov;31(11):769-76 PMID: 1385343
  5. US cancer incidence and mortality in the first year of life.
    Am J Dis Child. 1979 Feb;133(2):157-9 PMID: 420185
  6. Epipodophyllotoxins and secondary leukaemia.
    Lancet. 1993 Oct 2;342(8875):819-20 PMID: 8104269
  7. Occupational exposures of parents of children with acute nonlymphocytic leukemia: a report from the Childrens Cancer Study Group.
    Cancer Res. 1989 Jul 15;49(14):4030-7 PMID: 2736544
  8. Does bulk damage to DNA explain the cytostatic and cytotoxic effects of topoisomerase II inhibitors?
    Biochem Pharmacol. 1991 Nov 27;42(12):2253-8 PMID: 1662508
  9. Rapid evaluation of topoisomerase inhibitors: caffeine inhibition of topoisomerases in vivo.
    Teratog Carcinog Mutagen. 1990;10(1):41-52 PMID: 1971968
  10. Control selection using random digit dialing for cases of childhood cancer.
    Am J Epidemiol. 1984 Jul;120(1):164-6 PMID: 6741917
  11. The reliability of questionnaire-derived historical dietary information and temporal stability of food habits in individuals.
    Am J Epidemiol. 1984 Aug;120(2):281-90 PMID: 6465126
  12. Maternal drug use and risk of childhood nonlymphoblastic leukemia among offspring. An epidemiologic investigation implicating marijuana (a report from the Childrens Cancer Study Group).
    Cancer. 1989 May 15;63(10):1904-11 PMID: 2649219
  13. Topoisomerases in human disease.
    Lancet. 1988 Mar 5;1(8584):521-4 PMID: 2893929
  14. Association of paternal diagnostic X-ray exposure with risk of infant leukemia. Investigators of the Childrens Cancer Group.
    Cancer Epidemiol Biomarkers Prev. 1994 Dec;3(8):645-53 PMID: 7881337
  15. Epidemiology of childhood leukemia, with a focus on infants.
    Epidemiol Rev. 1994;16(2):243-72 PMID: 7713179
  16. Pediatric cancer in the United States. A preliminary report of a collaborative study of the Childrens Cancer Group and the Pediatric Oncology Group.
    Cancer. 1993 May 15;71(10 Suppl):3415-21 PMID: 8490892
  17. Childhood leukemia and parents' occupational and home exposures.
    J Natl Cancer Inst. 1987 Jul;79(1):39-46 PMID: 3474448
  18. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia.
    N Engl J Med. 1989 Jul 20;321(3):136-42 PMID: 2787477
  19. Infant leukemia, topoisomerase II inhibitors, and the MLL gene.
    J Natl Cancer Inst. 1994 Nov 16;86(22):1678-80 PMID: 7966394
  20. Site-specific DNA cleavage by mammalian DNA topoisomerase II induced by novel flavone and catechin derivatives.
    Biochem J. 1992 Mar 15;282 ( Pt 3):883-9 PMID: 1313232
  21. Common region of ALL-1 gene disrupted in epipodophyllotoxin-related secondary acute myeloid leukemia.
    Cancer Res. 1993 Jul 1;53(13):2954-6 PMID: 8319201
  22. Mechanisms of action of teniposide (VM-26) and comparison with etoposide (VP-16).
    Semin Oncol. 1992 Apr;19(2 Suppl 6):3-19 PMID: 1329225
  23. In utero rearrangements in the trithorax-related oncogene in infant leukaemias.
    Nature. 1993 May 27;363(6427):358-60 PMID: 8497319
  24. Retrospective assessment of dietary intake.
    Am J Epidemiol. 1984 Dec;120(6):876-87 PMID: 6507428
Article Info
Journal
Cancer causes & control : CCC
Abbr.
Cancer Causes Control
ISSN
0957-5243
Published
1996-11-00
Pages
581-90
Language
English
Region
Netherlands
NLM ID
9100846
Subset
IM
Grants
NCI NIH HHS · CA42479 · United States
NCI NIH HHS · CA49450 · United States
PHS HHS · T32 09607 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com